COSMED will attend the European and International Virtual Congress on Obesity - ECO ICO from 1 to 4 September 2020.

Venerdì 3 luglio COSMED partecipa al webinar organizzato dal gruppo di lavoro SISMES con un intervento su “Utilizzo dei filtri antivirali durante i test da sforzo: analisi e risultati”.

COSMED Announces Acquisition of Innovision Technology to Expand Product Portfolio and Presence in the Nordic Markets.

COSMED headquartered in Rome, Italy, leading manufacturer of Metabolic and Body composition technologies, has acquired assets of Innovision ApS, a Danish Company with significant know-how and expertise in the design of products for Hemodynamic (Cardiac Output), Ventilation Heterogeneity (Lung Clearance Index) and Metabolic measurements (VO2Max).

COSMED is glad to announce the U.S. Food and Drug Administration (FDA) clearance of Q-NRG+ and Q-NRG, a metabolic monitoring device utilizing Indirect Calorimetry (IC) technology intended for the measurement of Resting Energy Expenditure (REE) in patients who are mechanically ventilated or spontaneously breathing.

During these exceptional times, we would like to inform you that COSMED is adapting to the COVID-19 situation with diligence and is trying to face this big challenge with determination.

We wanted to take a moment to share with our customers, partners and communities how COSMED is responding to this evolving situation.